期刊文献+

99Tcm-(HYNIC-[Lys3]-BBS)(tricine)(tricine)的制备及对胰腺癌荷瘤鼠显像研究 被引量:2

Preparation and evaluation of 99Tcm-( HYNIC- [ Lys3 ] -bombesin) (tricine) (TPPTS) for imaging the Balb/c nude mice bearing human pancreatic cancer
原文传递
导出
摘要 目的制备99Tcm-(联肼尼克酰胺-蛙皮素类似肽)(N-三羟甲基甘氨酸)(三苯基膦三间磺酸钠盐)[(HYNIC-[Lys3]-BBS)(tricine)(TPPTS)]三重配位化合物,评价其在正常小鼠及胰腺癌荷瘤裸小鼠的生物分布。方法双功能螯合剂HYNIC与[Lys3]-BBS偶联(pH值9.0),以SnCl2为还原剂,tricine和TPPTS为协同配体,进行99Tcm-标记,合成三重配位化合物99Tcm-(HYNIC-[Lys。]-BBS)(tricine)(TPPTS)。用Sep-PakC18cartridge和HPLC对其纯化和分析,测定其标记率和放化纯,研究其在人血清中的稳定性,并进行正常小鼠体内的生物分布研究以及胰腺癌荷瘤裸小鼠活体显像。结果99Tcm-(HYNIC_[Lys3]-BBS)(tricine)(TPPTS)标记率为(90±2)%,放化纯〉95%,在人血清中放置4h其放化纯仍大于85%。正常小鼠体内分布结果表明,99Tcm-(HYNIC-[Lys3]-BBS)(tricine)(TPPTS)血液清除迅速,2h血液中放射性为(0.07±0.01)%ID/g,主要经。肾排泄,肝、胃肠道摄取较少,2h时肝放射性为(0.27±0.03)%ID/g,胃为(0.06±0.03)%ID/g,肠为(0.04±0.00)%ID/g。胰腺癌荷瘤裸小鼠吖显像可见肿瘤部位有放射性浓聚影,2h后肿瘤与对侧正常肌肉的T/NT比值最高达3.71±0.57。结论99Tcm-(HYNIC-[Lys3]-BBS)(tricine)(TPPTS)三重配位化合物制备成功,所用标记方法可行,标记物稳定性较好,标记率和放化纯较高,生物分布特性良好,有望用于胰腺癌的显像研究。 Objective To synthesize 99Tcm- ( hydrazinonictinamide-[ Lys3 ] -bombesin) (tricine) ( trisodium triphenylphosphine-3,3',3-trisulfonate) ( ( HYNIC-[ Lys3 ] -BBS) (tricine) (TPPTS) ) and e- valuate its biodistribution and binding capability with tumor tissue in Balb/c nude mice bearing human pan- creatic cancer xenografts. Methods HYNIC was conjugated to the [ Lys3 ] -BBS at pH : 9.0 with SnC12 as reducing agent and both tricine and TPPTS as coligands for 99Tcm-labeling. 99Tcm-HYNIC-[ Lys3] -BBS) (tricine) (TPPTS) was purified by Sep-Pak C18 cartridge and was analysed by HPLC. The radiochemical purity and radiolabeling yield were measured. The stability of 99Tcm-( HYNIC-[ Lys3 ]-BBS) (tricine) (TPPTS) in serum, biodistribution (% ID/g) in the normal mice and imaging of the Balb/c nude mice bearing human pancreatic cancer xenografts in vivo were studied. Results The radiolabeling yield was (90 ± 2)% and the radiochemical purity was over 95%. The radiochemical purity after d h in serum was over 85%. The distribution in normal mice showed rapid clearance from blood (the uptake was (0.07±0.01) %ID/g at 2 h postinjection). 99Tcm-( HYNIC-[ Lys3 ]-BBS) (tricine) (TPPTS) was excreted mainly via the kidney with little radioactivity accumulation in the liver and gastrointestinal tract (the uptake of liver, stomach, in- testine was (0.27 ±0.03), (0.06 ±0.03), (0.04 ±0.00) %ID/g at 2 h postinjection). Marked uptake of radioactivity was found in tumor tissue of the Balb/c nude mice bearing human pancreatic cancer withmaximum T/NT ratio of 3.71± 0.57 at 2 h postinjection. Conclusions 99 Tern_( HYNIC-[ Lys3 ]-BBS) (tricine) (TPPTS) can be easily prepared with high radiolabeling yield and radiochemical purity. The stability in serum and good biodistribution charateristics make it useful for the diagnosis of human pancreatic cancer with over-expression of the gastric-releasing peptide(GRP) receptor.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2011年第1期9-13,共5页 Chinese Journal of Nuclear Medicine
基金 基金项目:国家自然科学基金(30700186)
关键词 蛙皮素 化学合成 胰腺肿瘤 放射性核素显像 小鼠 Bombesin Technetium Chemical synthesis Pancreatic neoplasms Radionuclide imaging Mice, nude
  • 相关文献

参考文献12

  • 1李兆申.胰腺癌的治疗进展[J].中华内科杂志,2008,47(6):454-455. 被引量:1
  • 2Reubi JC,K(o)rner M,Waser B,et al.High expression of peptide receptors as a novel target in gastrointestinal stromal tumours.Eur J Nucl Med Mol Imaging,2004,31:803-810.
  • 3Kroog GS,Jensen RT,Battey JF.Mammalian bombesin receptors.Med Res Rev,1995,15:389-417.
  • 4Ferro-Flores G,Arteaga de Murphy C,Rodriguez-Cortés J,et al.Preparation and evaluation of 99Tcm-EDDA/HYNIC-[Lys3] -bombesin for imaging gastrin releasing peptide receptor-positive tumours.Nucl Med Commun,2006,27:371-376.
  • 5Shi J,Jia B,Liu Z,et al.99Tcm-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.Bioconjug Chem,2008,19:1170-1178.
  • 6La Bella R,Garcia-Garayoa E,Langer M,et al.in vitro and in vivo evaluation of a 99Tcm (Ⅰ)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors.Nucl Med Biol,2002,29:553-560.
  • 7Meszaros LK,Dose A,Biagini SCG,et al.Hydrazinonicotinic acid (HYNIC)-Coordination chemistry and applications in radiopharmaceutical chemistry.Inorg Chim Acta,2010,363:1059-1069.
  • 8Baidoo KE,Lin KS,Zham Y,et al.Design,synthesis,and initial evaluation of high-affinity technetium bombesin analogues.Bioconjug Chem,1998,9:218-225.
  • 9Weiner RE,Thakur ML.Radiolabeled peptides in oncology (role in diagnosis and treatment).Biodrugs,2005,19:145-163.
  • 10兰晓莉,张永学,安锐,高再荣,曹国祥.~99TC^m-HYNIC-Annexin V的制备及其在健康小鼠体内的分布[J].中华核医学杂志,2005,25(6):344-346. 被引量:9

二级参考文献42

  • 1金震东,李兆申,刘岩,杜奕奇,王洛伟,湛先保,陈洁.超声内镜引导下定向植入放射性^(125)I粒子治疗胰腺癌的临床研究[J].中华消化内镜杂志,2006,23(1):15-18. 被引量:53
  • 2陈洁,金震东,李兆申,江月萍,湛先保,王洛伟.内镜超声引导下瘤内注射重组人p53腺病毒治疗胰腺癌的短期临床观察[J].胰腺病学,2007,7(2):75-77. 被引量:8
  • 3Van Custem E, van de Velde, Karasek P,et al. Phase Ⅲ trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004, 22: 1430-1438.
  • 4Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ trial. J Clin Oncol, 2004, 22: 2610-2616.
  • 5Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007,25 : 1960-1966.
  • 6Hicklin D J, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005,23 : 1011-1027.
  • 7Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy, 2006,38:399-403.
  • 8Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev ,2006, 3 : CD002093.
  • 9Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control, 2004, 11 : 32-38.
  • 10Cai W, Gambhir SS, Chen X. Multimodality tumor imaging targeting integrin αvβ3. Biotechniques, 2005, 39: S6-S17.

共引文献16

同被引文献14

  • 1兰晓莉,张永学,安锐,高再荣,曹国祥.~99TC^m-HYNIC-Annexin V的制备及其在健康小鼠体内的分布[J].中华核医学杂志,2005,25(6):344-346. 被引量:9
  • 2Goldsmith SJ,Parsons W,Guiberteau MJ,et al.SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0.J Nucl Med Technol,2010,38:219-224.
  • 3Ferro-Flores G,Arteaga de Murphy C,Rodriguez-Cortés J,et al.Preparation and evaluation of 99Tcm-EDDA/HYNIC-[Lys3] -bombesin for imaging gastrin releasing peptide-receptor positive tumors.Nucl Med Commun,2006,27:371-376.
  • 4Jia B,Shi J,Yang Z,et al.99Tcm-labeled cyclic RGDfK dimer:initial evaluation for SPECT imaging of glioma integrin alphavbeta3expression.Bioconjug Chem,2006,17:1069-1706.
  • 5Shi J,Jia B,Liu Z,et al.99Tcm-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.Bioconjug Chem,2008,19:1170-1178.
  • 6Yang J,Guo H,Padilla RS,et al.Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of 99Tcm-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide.Bioorg Med Chem,2010,18:6695-6700.
  • 7Liu S,Hsieh W,Jiang Y,et al.Evaluation of a 99Tcm-labeled cyclic RGD tetramer for noninvasive imaging integrin αvβ3-positive breast cancer.Bioconjug Chem,2007,18:438-446.
  • 8Haubner R,Weber WA,Beer AJ,et al.Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and 18F-Galacto-RGD.PLoS Med,2005,2:e70.
  • 9Wang L,Shi J,Kim Y,et al.Improving tumor-targeting capability and pharmacokinetics of 99Tcm-labeled cyclic RGD dimers with PEG4 linkers.Mol Pharm,2009,6:231-245.
  • 10Liu Z,Jia B,Shi J,et al.Tumor uptake of the RGD dimeric probe 99Tcm-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.Bioconjug Chem,2010,21:548-555.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部